GlycoMimetics Net Income 2012-2025 | CBIO
GlycoMimetics net income from 2012 to 2025. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
GlycoMimetics Annual Net Income
(Millions of US $) |
| 2024 |
$-38 |
| 2023 |
$-37 |
| 2022 |
$-47 |
| 2021 |
$-63 |
| 2020 |
$-51 |
| 2019 |
$-58 |
| 2018 |
$-48 |
| 2017 |
$-33 |
| 2016 |
$-32 |
| 2015 |
$-13 |
| 2014 |
$-11 |
| 2013 |
$-11 |
| 2012 |
$4 |
| 2011 |
$-6 |
GlycoMimetics Quarterly Net Income
(Millions of US $) |
| 2025-03-31 |
$-2 |
| 2024-12-31 |
$-7 |
| 2024-09-30 |
$-10 |
| 2024-06-30 |
$-10 |
| 2024-03-31 |
$-11 |
| 2023-12-31 |
$-9 |
| 2023-09-30 |
$-9 |
| 2023-06-30 |
$-8 |
| 2023-03-31 |
$-10 |
| 2022-12-31 |
$-10 |
| 2022-09-30 |
$-9 |
| 2022-06-30 |
$-13 |
| 2022-03-31 |
$-15 |
| 2021-12-31 |
$-17 |
| 2021-09-30 |
$-17 |
| 2021-06-30 |
$-14 |
| 2021-03-31 |
$-14 |
| 2020-12-31 |
$-16 |
| 2020-09-30 |
$-14 |
| 2020-06-30 |
$-14 |
| 2020-03-31 |
$-8 |
| 2019-12-31 |
$-15 |
| 2019-09-30 |
$-13 |
| 2019-06-30 |
$-16 |
| 2019-03-31 |
$-14 |
| 2018-12-31 |
$-14 |
| 2018-09-30 |
$-12 |
| 2018-06-30 |
$-11 |
| 2018-03-31 |
$-12 |
| 2017-12-31 |
$-9 |
| 2017-09-30 |
$-8 |
| 2017-06-30 |
$-8 |
| 2017-03-31 |
$-8 |
| 2016-12-31 |
$-8 |
| 2016-09-30 |
$-8 |
| 2016-06-30 |
$-8 |
| 2016-03-31 |
$-8 |
| 2015-12-31 |
$-9 |
| 2015-09-30 |
$-7 |
| 2015-06-30 |
$10 |
| 2015-03-31 |
$-7 |
| 2014-12-31 |
$-7 |
| 2014-09-30 |
$-7 |
| 2014-06-30 |
$8 |
| 2014-03-31 |
$-5 |
| 2013-12-31 |
$-4 |
| 2013-09-30 |
$-4 |
| 2013-06-30 |
$-3 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.009B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
